Evaxion Biotech A/S

Evaxion Biotech A/S engages in the discovery and development of novel immunotherapies for cancer and infectious diseases. It uses its proprietary AI technology, engineering expertise and drug development know-how to simulate the human immune system and generate predictive models to identify and develop efficacious immunotherapies for patients in the global market. The company was founded by Niels Iversen Møller and Andreas Holm Mattsson on August 11, 2008 and is headquartered in Hoersholm, Denmark.

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Earnings data Q3 2025

Earnings data Q4 2025

Earnings data Q1 2026

Earnings data Q2 2026

Evaxion Biotech reports positive Q2 results and compliance plans

Evaxion Biotech A/S showcased strong performance in Phase II immune data.
The company is strategically positioned with a focused business model.
Challenges like compliance and financial impacts are being addressed proactively.

Evaxion Biotech reports strong 2024 performance and strategic growth

Evaxion Biotech's 2024 performance reflects progress in partnerships, clinical trials, and financial stability, setting a strong foundation for future growth. With a focus on innovative vaccine concepts and strategic acquisitions, Evaxion demonstrates resilience and potential for further advancements in the biotech industry. Challenges in optimizing spending and aligning strategic decisions with long-term goals underscore the need for operational efficiency and sustainable growth strategies. Opportunities in lead antigen selection, partnership leverage, and pipeline advancements position Evaxion for continued success and innovation in the evolving biotech landscape.

Evaxion Biotech (EVAX) reports solid Q1 performance and growth opportunities

Evaxion Biotech A/S (EVAX) demonstrated strong performance in Q1 2025, with a focus on financial stability, R&D innovation, and strategic partnerships. The company's strengths lie in its Merck partnership, R&D advancements, and proactive business development approach, despite market challenges. Challenges include market volatility impacting deal execution and the need for clarity on scientific and commercial strategies. Opportunities for Evaxion include potential financial gains from partnerships, expansion of vaccine pipelines, and market growth potential.

Evaxion Biotech (EVAX) reports strong Q2 performance and partnerships

Evaxion Biotech A/S demonstrates strong performance and progress in key R&D programs. Financially stable with cash at hand until mid-2026 and debt settlement enhancing position. Challenges exist in deal execution and analyst queries on partnership progress. Opportunities lie in potential value catalysts and ongoing business development discussions.

Evaxion Biotech (EVAX) reports robust Q3 performance and strategic advancements

Evaxion Biotech (EVAX) showcases strong financial performance, promising clinical outcomes, and strategic advancements in vaccine development and partnerships. While facing potential uncertainties with MSD's evaluation of EVX-B2, the company's strengthened financial position and innovative pipeline position it well for future growth. New CEO appointment, introduction of EVX-04, and enhanced AI-Immunology platform offer avenues for growth, market expansion, and revenue diversification.

Evaxion Biotech (EVAX) excels in Q4 2025, poised for growth

Evaxion Biotech (EVAX) delivered a robust performance in Q4 2025, showcasing advancements in R&D, strategic collaborations, and financial strength. The company's focus on cancer vaccine programs, AI technology, and cash position extension positions it well for future growth and innovation. While facing challenges in program sustainability and market dynamics, Evaxion remains poised to leverage opportunities in expanding its portfolio and market presence.

Evaxion Biotech (EVAX) excels in Q1 2026, eyes strategic growth

Evaxion Biotech shows strong performance in Q1 2026 with promising data and financial stability Emphasis on partnerships, asset scalability, and strategic planning for future growth Challenges lie in sustaining momentum, meeting expectations, and financial management Opportunities abound in partnerships, technology advancements, and leveraging study results

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Evaxion AS engages in the discovery and development of immunotherapies for cancer and infectious diseases. Its technologies include the immuno-oncology platform PIONEER, the bacterial disease platform EDEN, the viral disease platform RAVEN, and the proprietary AI platform technology ObsERV. The company was founded by Niels Iversen Møller and Andreas Holm Mattsson on August 11, 2008 and is headquartered in Hoersholm, Denmark.